OneDigital Investment Advisors LLC Reduces Stock Position in Humana Inc. (NYSE:HUM)

OneDigital Investment Advisors LLC lowered its stake in shares of Humana Inc. (NYSE:HUM) by 4.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,113 shares of the insurance provider’s stock after selling 51 shares during the period. OneDigital Investment Advisors LLC’s holdings in Humana were worth $282,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FPC Investment Advisory Inc. purchased a new stake in shares of Humana in the fourth quarter worth $27,000. Centricity Wealth Management LLC purchased a new stake in shares of Humana in the fourth quarter worth $30,000. LFA Lugano Financial Advisors SA raised its position in shares of Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares in the last quarter. OFI Invest Asset Management purchased a new stake in shares of Humana in the fourth quarter worth $33,000. Finally, Transce3nd LLC purchased a new stake in shares of Humana in the fourth quarter worth $38,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Guggenheim assumed coverage on Humana in a research report on Wednesday, April 9th. They issued a “buy” rating and a $326.00 price objective on the stock. JPMorgan Chase & Co. reduced their target price on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $283.00 target price on shares of Humana in a research note on Wednesday, February 12th. Barclays increased their target price on Humana from $270.00 to $322.00 and gave the company an “equal weight” rating in a research note on Friday, April 11th. Finally, Robert W. Baird increased their target price on Humana from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, April 15th. Seventeen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus target price of $284.90.

Humana Stock Down 0.5 %

NYSE HUM opened at $263.08 on Tuesday. The business’s 50-day moving average is $266.31 and its 200 day moving average is $270.84. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The stock has a market capitalization of $31.75 billion, a PE ratio of 26.44, a PEG ratio of 2.05 and a beta of 0.62. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46.

Humana (NYSE:HUM) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Sell-side analysts forecast that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.35%. Humana’s payout ratio is 35.58%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.